Article information
Resumen
La vasculopatía livedoide es una entidad rara y crónica que afecta predominantemente los miembros inferiores. La etiología de la enfermedad es desconocida, pero en la histopatología se observa trombosis en la dermis sin compromiso inflamatorio de la pared del vaso. Se manifiesta por lesiones petequiales y por ulceraciones que sanan con cicatrices hiperpigmentadas alternando con áreas blanquecinas. Se han empleado múltiples tratamientos hasta el momento, sin total éxito.
Palabras clave:
síndrome antifosfolípido
livedo reticularis
fisiopatología
terapia
Summary
Livedoid vasculopathy is a rare, chronic disease that affects predominantly the lower limbs. The etiology of the disease is unknown, but histopathology shows thrombosis in the dermis without inflammatory changes in the vessel wall. It is manifested by petechial lesions and ulcerations that heal with scarring hyperpigmentation alternating with white areas. Multiple treatments have been used so far, without total success.
Key words:
antiphospholipid syndrome
reticularis livedo
pathophysiology
therapy
Full text is only aviable in PDF
Referencias
[1.]
B. Hairston, M. Davis, M. Pittelkow, I. Ahmed.
Livedoid vasculopathy: further evidence for procoagulant pathogenesis.
Arch Dermatol, 142 (2006), pp. 1413-1418
[2.]
J. Bard, R. Winkelmann.
Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.
Arch Dermatol, 96 (1967), pp. 489-499
[3.]
G. Milian.
Les atrophies cutanées syphilitiques.
Bull Soc Franc Derm Syph, 36 (1929), pp. 865-871
[4.]
R. Winkelmann, A. Schroeter, R. Kierland, T. Ryan.
Clinical studies of livedoid vasculitis: segmental hyalinizing vasculitis.
Mayo Clin Proc, 49 (1974), pp. 746-750
[5.]
M. Papi, B. Didona, O. De Pita, L. Silvestri, G. Ferranti, M. Gantcheva, L. Chinni.
PURPLE (atrophie blanche): Clinical, histological and immunological study of twelve patients.
J Eur Acad Dermatol Venereol, 9 (1997), pp. 129-133
[6.]
M. Maessen-Visch, M. Koedam, K. Hamulyák, H. Neumann.
Atrophie blanche.
Int J Dermatol, 38 (1999), pp. 161-172
[7.]
K. Tsutsui, F. Shirasaki, M. Takata, K. Takehara.
Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
Dermatol, 192 (1996), pp. 120-124
[8.]
M. Baccard, M. Vignon-Pennamen, M. Janier, M. Scrobohaci, L. Dubertret.
Livedo vasculitis with protein C system deficiency.
Arch Dermatol, 128 (1992), pp. 1410-1411
[9.]
B. Hegemann, P. Helmbold, W. Marsch.
Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences.
Arch Dermatol, 138 (2002), pp. 841-842
[10.]
C. Drucker, W. Duncan.
Antiplatelet therapy in atrophie blanche and livedo vasculitis.
J Am Acad Dermatol, 7 (1982), pp. 359-363
[11.]
F. Meiss, W. Marsch, M. Fischer.
Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences.
Eur J Dermatol, 16 (2006), pp. 159-162
[12.]
I. Uthman, M. Khamashta.
Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome.
J Rheumatol, 33 (2006), pp. 2379-2382
[13.]
C. Grattan, J. Burton, A. Boon.
Sneddon's syndrome (livedo reticularis and cerebral thrombosis) with livedo vasculitis and anticardiolipin antibodies.
Br J Dermatol, 120 (1989), pp. 441-447
[14.]
K. Acland, A. Darvay, S. Wakelin, R. Russell-Jones.
Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?.
Br J Dermatol, 140 (1999), pp. 131-135
[15.]
J. Grob, J. Bonerandi.
Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity.
J Am Acad Dermatol, 20 (1989), pp. 1063-1069
[16.]
A. Leonard, M. Pomeranz, A. Franks Jr..
A case of livedoid vasculopathy in a 22-year-old man.
J Drugs Dermatol, 3 (2004), pp. 678-679
[17.]
S. In, J. Han, H. Kang, E. Lee, Y. Kim.
The histopathological characteristics of livedo reticularis.
J Cutan Pathol, 36 (2009), pp. 1275-1278
[18.]
A. Shimizu, A. Tamura, M. Yamanaka, H. Amano, Y. Nagai, O. Ishikawa.
Case of livedoid vasculopathy with extensive dermal capillary thrombi.
J Dermatol, 37 (2010), pp. 94-97
[20.]
S. Weinstein, W. Piette.
Cutaneous manifestations of antiphospholipid antibody syndrome.
Hematol Oncol Clin North Am, 22 (2008), pp. 67-77
[21.]
P. Criado, E. Rivitti, M. Sotto, J. de Carvalho.
Livedoid vasculopathy as a coagulation disorder.
Autoimmun Rev, 10 (2011), pp. 353-360
[22.]
T. Goerge.
Livedovaskulopathie. Pathogenese, Diagnostik und Therapie des Hautinfarkts.
Hautarzt, 62 (2011), pp. 627-636
[23.]
K. Klein, M. Pittelkow.
Tissue plasminogen activator for treatment of livedoid vasculitis.
Mayo Clin Proc, 67 (1992), pp. 923-933
[24.]
K. Hoogenberg, R. Tupker, L. van Essen, A. Smith, C. Kallenberg.
Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin.
Br J Dermatol, 127 (1992), pp. 64-66
[25.]
M. Yamamoto, K. Danno, H. Shio, S. Imamura.
Antithrombotic treatment in livedo vasculitis.
J Am Acad Dermatol, 18 (1988), pp. 57-62
[26.]
M. Rustin, C. Bunker, P. Dowd.
Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin.
Br J Dermatol, 120 (1989), pp. 101-105
[27.]
G. Hsiao, H. Chiu.
Low-dose danazol in the treatment of livedoid vasculitis.
Dermatol, 194 (1997), pp. 251-255
[28.]
G. Hsiao, H. Chiu.
Livedoid vasculitis. Response to lowdose danazol.
Arch Dermatol, 132 (1996), pp. 749-751
[29.]
B. Hairston, M. Davis, L. Gibson, L. Drage.
Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.
Arch Dermatol, 139 (2003), pp. 987-990
[30.]
J. Callen.
Livedoid vasculopathy: what it is and how the patient should be evaluated and treated.
Arch Dermatol, 142 (2006), pp. 1481-1482
[31.]
G. Pitarch, M. Rodríguez-Serna, A. Torrijos, V. Oliver, J. Fortea.
Treatment of livedoid vasculopathy with shortcycle intravenous immunoglobulins.
Acta Derm Venereol, 85 (2005), pp. 374-375
[32.]
P. Zeni, E. Finger, M. Scheinberg.
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy.
Ann Rheum Dis, 67 (2008), pp. 1055-1056
[33.]
S. Miyaki, M. Lockshin, T. Atsumi, D. Branch, R. Brey, R. Cervera, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost, (2006), pp. 295-306
[34.]
R. Rai, C. Sekar, M. Kumaresan.
Antiphospholipid syndrome in dermatology: An update.
Indian J Dermatol Venereol Leprol, 76 (2010), pp. 116-124
[35.]
R. Asherson, C. Francés, L. Iaccarino, M. Khamashta, F. Malacarne, J. Piette, et al.
The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy.
Clin Exp Rheumatol, 24 (2006), pp. 46-51
Copyright © 2011. Asociación Colombiana de Reumatología
